JAK1/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a pre-existing B-cell clone

In this study, we elucidated differential gene expression between transformed and untransformed murine Stat1 -/- B cells by RNA sequencing. In addition, clinical samples from 2 lymphoma patients were analyzed. Key results are that 1) JAK1/2 inhibitor treatment in myelofibrosis is associated with an increased risk for aggressive B-cell lymphomas and 2) patients at risk can be identified by screening for pre-existing B-cell clones in peripheral blood or bone marrow. Overall design: Differential gene expression between 2 murine groups. Clinical samples from 2 lymphoma patients.

本研究通过RNA测序（RNA sequencing）解析了转化型与非转化型小鼠Stat1基因纯合缺失（Stat1 -/-）B细胞间的差异基因表达谱。此外，本研究还对2名淋巴瘤患者的临床样本开展了分析。本研究的核心结果如下：1）骨髓纤维化患者接受JAK1/2抑制剂（JAK1/2 inhibitor）治疗后，罹患侵袭性B细胞淋巴瘤的风险显著升高；2）可通过对外周血或骨髓中预先存在的B细胞克隆进行筛查，识别出此类高风险患者。实验整体设计：对比两组小鼠的差异基因表达，并纳入2名淋巴瘤患者的临床样本。